This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cordis Announces FDA Clearance Of The ADROIT™ Guiding Catheter

Stocks in this article: JNJ

Cordis Corporation today announced it has received clearance from the Food and Drug Administration of its latest innovation in guiding catheters: the ADROIT TM 6F Guiding Catheter.

“The new ADROIT TM Guiding Catheter, allows physicians to have more options for treating a wide range of challenging cases. It accommodates easier advancement of devices with its 0.072’ diameter, the largest inner diameter of any guiding catheter in the U.S., while providing better support and control at the same time. These features enhance treatment options for physicians, including the treatment of cases with complex lesions and those to be conducted using the radial approach,” said Celine Martin, Worldwide President, Cordis Corporation.

The ADROIT TM Catheter’s innovative hybrid braid wire technology not only enables the production of a guide catheter with the largest lumen size on the U.S. market today, it also facilitates better control and back up support. In addition, the new innovative design incorporating a flexible distal segment and soft longer tip allows atraumatic placement and stability. The ADROIT TM Guiding Catheter provides a wide range of shapes, including extra back-up shapes and radial specific shapes to support treatment needs of various coronary anatomies.

“Our vision at Cordis is to transform cardiovascular care, a field in which incredible progress has been made over the last decade, but one in which much more remains to be done. We are excited for the launch of our new ADROIT TM Guiding Catheter as it complements our guide catheter portfolio with its technological and design advances. We will continue to deliver innovative solutions that save lives and improve the quality of life for people around the world,” concluded Martin.

About Cordis Corporation

Cordis Corporation, part of the Johnson & Johnson Family of Companies, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with physicians worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com (this site is intended for U.S. visitors).



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs